Cosopt Patent Remains Dead – Teva to Produce a Generic Version of the Glaucoma Treatment

April 11, 2011


A U.K. appeals court has rejected an attempt bid by Merck & Co. Inc. to revive a European patent covering Cosopt, paving the way for Teva UK Ltd. to push forth a generic version of the glaucoma treatment.
Merck & Co., is the second-biggest U.S. drug company. Teva UK is a subsidiary of Israel’s Teva Pharmaceutical Industries, the world’s biggest maker of generic drugs.
Teva sued Merck three years ago claims the patent shouldn’t have been granted after Merck filed the application in 1992. The Appeal upheld a November 2009 ruling that Merck’s patent lacked novelty or inventiveness was correct because experts in the field would have found the development to be obvious.
COSOPT (dorzolamide hydrochloride-timolol maleate ophthalmic solution) is the combination of a topical carbonic anhydrase inhibitor and a topical beta-adrenergic receptor blocking agent.
Glaucoma is a disease of the optic nerve which receives light-generated nerve impulses from the retina and transmits these to the brain, where we recognize those electrical signals as vision.
Glaucoma is characterized by a particular pattern of progressive damage to the optic nerve that generally begins with a subtle loss of side vision (peripheral vision). If glaucoma is not diagnosed and treated, it can progress to loss of central vision and blindness.


Reduction in PCT Search Fees at the EPO

March 22, 2010

As of 1 April 2010, the search fees payable to the EPO as an International Search Authority of the PCT will be $US 2485 instead of $US 2515, as previously.

This is not an April fools day joke.  I suspect that the reduction reflects the relative strengths of the Euro and the US Dollar, and possibly the fact that the USPTO is actually performing searches and not merely accepting payment for same.


Israel Patent Office Hosts European Biology/Chemistry Examiners

October 18, 2009

The Israel Patent Office hosted a seminar featuring examiners from the European Patent Office. The focus was on examining chemistry and genetic applications, and presentations covered examining Markush type claims, oppositions and unity of invention.

The presentations were fairly pedestrian and not very exciting. We learned that there is a two year deadline for filing divisional applications, but instead of explaining that annuities were required retroactively, which for the inexperienced can be a nasty shock, or giving useful tips, the presenter labored the straightforward 24 month point with examples! The cakes provided as refreshments were good, but the coffee and tea were Elite Instant, Botz (Turkish-’mud’ coffee, and Wissotzky blue label cheap and nasty tea bags.

One of the examiners spoke briefly in Hebrew albeit with a very strong French accent. the crowd applauded his efforts. Tomorrow, the same presentation is being presented at Haifa university and in Tel Aviv.

In terms of the content, not very interesting and perhaps not worth attending. However, the seminar did provide an opportunity to see the new patent office premises which are very impressive. The lecture theatre seats 120 on leatherette seats. There are good acoustics and nice projector equipment. We hope that the seminars for Examiners only will prove informative and that will improve examining standards.

One clear advantage of the Patent Office hosting seminars for the profession is that people from the different offices feel that the activity is for them, whereas many practitioners feel uncomfortable attending events organized by rival firms. A necessary consequence of official patent office patronage of IP seminars is that controversial and therefore, potentially more interesting topics are avoided.  Indeed, we think that for the patent office to become involved in anything beyond procedure, such as say discussing the scope of patentable material or other gray areas may be problematic as there is a conflict of interest between the profession and the patent office. Like all IP seminars aimed at the profession, the event provided a good opportunity to catch up with acquaintances.


But I’ll be true to the song I sing, And live and die a Pirate King!

June 8, 2009
The Pirate Party “Piratpartiet”, has won one of Sweden’s eighteen European Parliament seats in the European Parliament. The party’s platform includes legalising Internet file-sharing, and overhauling copyright and patent laws. Other issues in their manifesto include free access to the Internet.

1907poster

The party’s membership figures tripled within a week of the recent controversial Pirate Bay ruling by a Swedish court Read the rest of this entry »


European Commission Calls for single EU Patent

March 19, 2009

The European Commission has repeated its demand for a single European patent, stating that Read the rest of this entry »


EPO takes tough stance on missed deadline

June 29, 2008

A Board of Appeal of the European Patent Office has refused to reinstate a patent application after the professional Read the rest of this entry »


Israel Stands Up to US Pressure

March 20, 2008

Israel has informed the US government that it won’t enforce Digital Rights Management (DRM), nor will she Read the rest of this entry »


UK Patent Office Challenges Court Ruling re Software Patents

March 20, 2008

In a press release of the United Kingdom Patent Office, the office has decided to appeal a recent High Court Decision  Read the rest of this entry »


UK High Court Rules that Software is Patentable

January 26, 2008

The UK High Court has ruled that the British Patent Office is wrong to reject software Read the rest of this entry »


European Commission Raids Pharmaceutical Companies in Sector-Wide Inquiry on Patent Abuse

January 25, 2008

In a series of dawn raids on 16 January 2008, the European Commission (EC) carried out a number of unannounced inspections of both innovative (drug developing, pharma) and generic Read the rest of this entry »


Follow

Get every new post delivered to your Inbox.

Join 93 other followers